AbstractWe propose a new method for risk‐analytic benchmark dose (BMD) estimation in a dose‐response setting when the responses are measured on a continuous scale. For each dose leveld, the observationX(d) is assumed to follow a normal distribution:. No specific parametric form is imposed upon the meanμ(d), however. Instead, nonparametric maximum likelihood estimates ofμ(d) andσare obtained under a monotonicity constraint onμ(d). For purposes of quantitative risk assessment, a ‘hybrid’ form of risk function is defined for any dosedasR(d) =P[X(d) <c], wherec> 0 is a constant independent ofd. The BMD is then determined by inverting theadditional risk functionRA(d) =R(d) −R(0) at some specified value of benchmark response. Asymptotic theory for the point estimators is derived, and a finite‐sample study is conducted, using both real and simulated data. When a large number of doses are available, we propose an adaptive grouping method for estimating the BMD, which is shown to have optimal mean integrated squared error under appropriate designs.
Read full abstract